文献速递糖尿病

SGLT2抑制剂达格列净增加2型糖尿病患者摄入脂肪酸向酮体的氧化

The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2022-01-01

本研究为双盲、安慰剂对照、交叉设计,设4周洗脱期,2型糖尿病患者随机先后接受达格列净或安慰剂各4周;每阶段结束后摄入含[U-13C]棕榈酸的橄榄油并采血480分钟。达格列净使葡萄糖排泄率升高、外周葡萄糖摄取降低,血浆β-羟丁酸及[13C2]β-羟丁酸浓度升高、血糖降低;结论提示膳食来源脂肪酸参与达格列净治疗期间酮体升高。

要点

  • 达格列净较安慰剂使血浆β-羟丁酸及[13C2]β-羟丁酸浓度升高、血糖降低。
  • 达格列净较安慰剂使葡萄糖排泄率升高、外周葡萄糖摄取降低。
  • 研究者认为酮体升高源于肝脏内酮生成增加的代谢转换。

核心结论

  • 摄入棕榈酸示踪剂后酮体富集增加,提示膳食来源脂肪酸参与达格列净治疗期间酮体升高。
  • 达格列净使β-羟丁酸浓度升高,而血浆非酯化脂肪酸浓度仅轻微变化、脂解无变化,提示肝脏内酮生成增加的代谢转换。

研究设计与样本

  • 双盲、安慰剂对照、交叉研究,设4周洗脱期;参与者按随机顺序接受达格列净或安慰剂各4周。
  • 每阶段治疗后摄入30 mL含[U-13C]棕榈酸的橄榄油以测定酮生成,采血480分钟。
  • 在450-480分钟输注葡萄糖和甘油稳定同位素,分别测定葡萄糖通量和脂解。

主要发现

  • 达格列净较安慰剂葡萄糖排泄率更高、外周葡萄糖摄取更低。
  • 达格列净较安慰剂血浆β-羟丁酸浓度和[13C2]β-羟丁酸浓度更高、血糖浓度更低。
  • 达格列净较安慰剂非酯化脂肪酸在300分钟和420分钟更高,但450-480分钟脂解无差异。
  • 三酰甘油在所有时间点及450-480分钟内源性葡萄糖生成率两种治疗间无差异。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the mechanism for increased ketogenesis following treatment with the SGLT2 inhibitor dapagliflozin in people with type 2 diabetes. RESEARCH DESIGN AND METHODS: The design was a double-blind, placebo-controlled, crossover study with a 4-week washout period. Participants received dapagliflozin or placebo in random order for 4 weeks. After each treatment, they ingested 30 mL of olive oil containing [U-13C]palmitate to measure ketogenesis, with blood sampling for 480 min. Stable isotopes of glucose and glycerol were infused to measure glucose flux and lipolysis, respectively, at 450-480 min. RESULTS: Glucose excretion rate was higher and peripheral glucose uptake lower with dapagliflozin than placebo. Plasma β-hydroxybutyrate (BOHB) concentrations and [13C2]BOHB concentrations were higher and glucose concentrations lower with dapagliflozin than placebo. Nonesterified fatty acids (NEFAs) were higher with dapagliflozin at 300 and 420 min, but lipolysis at 450-480 min was not different. Triacylglycerol at all time points and endogenous glucose production rate at 450-480 min were not different between treatments. CONCLUSIONS: The increase in ketone enrichment from the ingested palmitic acid tracer suggests that meal-derived fatty acids contribute to the increase in ketones during treatment with dapagliflozin. The increase in BOHB concentration with dapagliflozin occurred with only minimal changes in plasma NEFA concentration and no change in lipolysis. This finding suggests a metabolic switch to increase ketogenesis within the liver.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Herring RA, Shojaee-Moradie F, Stevenage M, et al. The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes. Diabetes Care. 2022. PMID: 35312749. doi:10.2337/dc21-2043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。